DCI Announces Latest Release of SureLynx, the Leading Electronic Data Capture Application for Early Stage Clinical Trials
Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
MARIETTA, Ga., April 26, 2005 /PRNewswire/ -- Data Capture International, Inc. (DCI), an emerging Application Service Provider that offers Electronic Data Capture (EDC) software solutions and services to pharmaceutical companies and Contract Research Organizations (CRO's) that perform Phase I (early stage) human clinical trials, announced the release of SureLynx(TM) V2.0.
SureLynx is DCI's flagship product and consists of a software application for increasing efficiency, improving data quality, and providing standardization for the collection of data in Phase I clinical trials. In addition to the software application, state-of-the-art bar code technology and radio-frequency transmission are combined with approved clinical trial methodologies to yield a product and process that have been proven in the practical setting and provide significant advantages over other systems.
Troy W. McCall, Ph.D., President, said, "The release of SureLynx V2.0 marks an important milestone in our evolution. Our ongoing development efforts ensure that our clients will continue to use state-of-the-art technologies to gain competitive advantages in conducting early stage clinical trials."
"SureLynx is self-directed, self-checking, mobile, user-friendly, and compliant with the strict regulations set forth in 21 CFR Part 11," said Deborah Rucker, Vice President, Business Development. "Our experience, which spans more than 15 years with earlier versions, has been critical in developing the most adaptable system available in the market today."
Dr. McCall continued, "While there are numerous EDC applications available for the collection of clinical data, SureLynx is the only one designed exclusively for early stage trials. This ensures the highest quality data will be efficiently collected in a cost-competitive manner."
Company Background
Data Capture International, Inc. (DCI) was founded to enhance pharmaceutical development by providing value-added software solutions and services for Phase I clinical trials. The company's mission is to be the leading provider of automated identification and data capture technology and systems supporting pharmaceutical product development.
CONTACT: Deborah Rucker, Vice President, Business Development of DataCapture International, Inc., +1-813-654-0132, or drucker@datacaptureintl.com
Web site: www.datacaptureintl.com/
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
